JP2009514840A - インフルエンザワクチンによってプライム(priming)/ブースト(boosting)するための投与経路 - Google Patents

インフルエンザワクチンによってプライム(priming)/ブースト(boosting)するための投与経路 Download PDF

Info

Publication number
JP2009514840A
JP2009514840A JP2008538419A JP2008538419A JP2009514840A JP 2009514840 A JP2009514840 A JP 2009514840A JP 2008538419 A JP2008538419 A JP 2008538419A JP 2008538419 A JP2008538419 A JP 2008538419A JP 2009514840 A JP2009514840 A JP 2009514840A
Authority
JP
Japan
Prior art keywords
vaccine
influenza
mucosal
parenteral
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008538419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514840A5 (https=
Inventor
マイケル バジディ,
デレック オハガン,
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Publication of JP2009514840A publication Critical patent/JP2009514840A/ja
Publication of JP2009514840A5 publication Critical patent/JP2009514840A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008538419A 2005-11-04 2006-11-06 インフルエンザワクチンによってプライム(priming)/ブースト(boosting)するための投与経路 Pending JP2009514840A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US83633206P 2006-08-07 2006-08-07
PCT/GB2006/004132 WO2007052057A2 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines

Publications (2)

Publication Number Publication Date
JP2009514840A true JP2009514840A (ja) 2009-04-09
JP2009514840A5 JP2009514840A5 (https=) 2009-10-15

Family

ID=37862714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008538419A Pending JP2009514840A (ja) 2005-11-04 2006-11-06 インフルエンザワクチンによってプライム(priming)/ブースト(boosting)するための投与経路

Country Status (7)

Country Link
US (1) US20100158943A1 (https=)
EP (1) EP1945253A2 (https=)
JP (1) JP2009514840A (https=)
AU (1) AU2006310338A1 (https=)
CA (1) CA2628379A1 (https=)
NZ (1) NZ567980A (https=)
WO (1) WO2007052057A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502995A (ja) * 2012-12-17 2016-02-01 ユーロシネ ヴァクシンズ アクチエボラーグ 鼻腔内予防接種投薬レジメン

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007258874B2 (en) 2006-06-15 2013-11-14 Seqirus UK Limited Adjuvant-sparing multi-dose influenza vaccination regimen
EP2173376B1 (en) * 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
WO2009115917A2 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
JP5712126B2 (ja) * 2008-06-25 2015-05-07 ノバルティス アーゲー 遅延型追加刺激免疫処置に対する迅速な応答
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
SI2396030T1 (sl) 2009-02-10 2015-12-31 Novartis Ag Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo
ES2739711T3 (es) * 2010-07-22 2020-02-03 John W Schrader Anticuerpo de protección cruzada contra la infección por el virus de la gripe
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500099A (ja) * 1993-12-22 1998-01-06 カイロン エセ.ピー.アー. 非毒性の粘膜アジュバント
JP2003509473A (ja) * 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
JP2003510291A (ja) * 1999-09-30 2003-03-18 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US5643574A (en) * 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US20040213745A1 (en) * 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500099A (ja) * 1993-12-22 1998-01-06 カイロン エセ.ピー.アー. 非毒性の粘膜アジュバント
JP2003509473A (ja) * 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
JP2003510291A (ja) * 1999-09-30 2003-03-18 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012017838; Hashigucci, K. et al.: Vaccine Vol.14, No.2, 1996, pp.113-119 *
JPN6012017840; Asanuma, H. et al.: Vaccine Vol.13, No.1, 1995, pp.3-5 *
JPN6012017843; Lee, C.K. et al.: Vaccine Vol.17, 1999, pp.3072-3082 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502995A (ja) * 2012-12-17 2016-02-01 ユーロシネ ヴァクシンズ アクチエボラーグ 鼻腔内予防接種投薬レジメン
JP2018172434A (ja) * 2012-12-17 2018-11-08 ユーロシネ ヴァクシンズ アクチエボラーグ 鼻腔内予防接種投薬レジメン

Also Published As

Publication number Publication date
EP1945253A2 (en) 2008-07-23
AU2006310338A1 (en) 2007-05-10
CA2628379A1 (en) 2007-05-10
NZ567980A (en) 2012-01-12
US20100158943A1 (en) 2010-06-24
WO2007052057A2 (en) 2007-05-10
WO2007052057A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
JP7427648B2 (ja) 卵を使用しないインフルエンザウイルスワクチンの作製
JP5566687B2 (ja) アジュバントを使用しない複数回投与ワクチン接種レジメン
JP5957176B2 (ja) H5インフルエンザa型ウイルスの複数のクレードを使用する予防接種
JP6275229B2 (ja) 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
JP2018184450A (ja) アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
JP2010531348A5 (https=)
JP2010531348A (ja) 添加剤の少ないインフルエンザワクチン
JP2009514841A (ja) 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
JP2011506264A (ja) インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
JP2012167123A (ja) サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
JP5518041B2 (ja) インフルエンザウイルスワクチン抗原の調製における改良
JP2009534303A (ja) 冷蔵しないインフルエンザワクチンの保存
JP2009514844A (ja) スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
JP5363107B2 (ja) アジュバントを含むスプリットインフルエンザワクチンにおけるth1/th2バランスの変化
JP2009514840A (ja) インフルエンザワクチンによってプライム(priming)/ブースト(boosting)するための投与経路
JP5005700B2 (ja) アルミニウムアジュバントに即座に吸着されるインフルエンザワクチン
JP2009514838A (ja) 細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
JP2014015486A (ja) インフルエンザウイルスの4つの株に由来する抗原を含むワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130924